vs
Innovex International, Inc.（INVX）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Innovex International, Inc.的季度营收约是Ultragenyx Pharmaceutical Inc.的1.3倍（$273.6M vs $207.3M），Innovex International, Inc.净利率更高（5.1% vs -62.0%，领先67.1%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 9.1%），过去两年Innovex International, Inc.的营收复合增速更高（46.2% vs 38.0%）
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
INVX vs RARE — 直观对比
营收规模更大
INVX
是对方的1.3倍
$207.3M
营收增速更快
RARE
高出16.8%
9.1%
净利率更高
INVX
高出67.1%
-62.0%
两年增速更快
INVX
近两年复合增速
38.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $273.6M | $207.3M |
| 净利润 | $14.0M | $-128.6M |
| 毛利率 | 28.9% | — |
| 营业利润率 | 9.4% | -54.7% |
| 净利率 | 5.1% | -62.0% |
| 营收同比 | 9.1% | 25.9% |
| 净利润同比 | -56.1% | 3.5% |
| 每股收益（稀释后） | $0.20 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收INVXRARE
| Q4 25 | $273.6M | $207.3M | ||
| Q3 25 | $240.0M | $159.9M | ||
| Q2 25 | $224.2M | $166.5M | ||
| Q1 25 | $240.4M | $139.3M | ||
| Q4 24 | $250.7M | $164.6M | ||
| Q3 24 | $151.8M | $139.5M | ||
| Q2 24 | $130.3M | $147.0M | ||
| Q1 24 | $128.0M | $108.8M |
净利润INVXRARE
| Q4 25 | $14.0M | $-128.6M | ||
| Q3 25 | $39.2M | $-180.4M | ||
| Q2 25 | $15.3M | $-115.0M | ||
| Q1 25 | $14.8M | $-151.1M | ||
| Q4 24 | $31.8M | $-133.2M | ||
| Q3 24 | $82.6M | $-133.5M | ||
| Q2 24 | $9.5M | $-131.6M | ||
| Q1 24 | $16.4M | $-170.7M |
毛利率INVXRARE
| Q4 25 | 28.9% | — | ||
| Q3 25 | 31.6% | — | ||
| Q2 25 | 32.0% | — | ||
| Q1 25 | 31.8% | — | ||
| Q4 24 | 33.9% | — | ||
| Q3 24 | 34.7% | — | ||
| Q2 24 | 35.3% | — | ||
| Q1 24 | 38.4% | — |
营业利润率INVXRARE
| Q4 25 | 9.4% | -54.7% | ||
| Q3 25 | 26.0% | -106.9% | ||
| Q2 25 | 10.1% | -64.8% | ||
| Q1 25 | 9.1% | -102.6% | ||
| Q4 24 | 10.7% | -74.3% | ||
| Q3 24 | -8.7% | -94.6% | ||
| Q2 24 | 10.0% | -79.1% | ||
| Q1 24 | 17.4% | -151.9% |
净利率INVXRARE
| Q4 25 | 5.1% | -62.0% | ||
| Q3 25 | 16.3% | -112.8% | ||
| Q2 25 | 6.8% | -69.0% | ||
| Q1 25 | 6.1% | -108.5% | ||
| Q4 24 | 12.7% | -80.9% | ||
| Q3 24 | 54.4% | -95.7% | ||
| Q2 24 | 7.3% | -89.5% | ||
| Q1 24 | 12.8% | -156.8% |
每股收益（稀释后）INVXRARE
| Q4 25 | $0.20 | $-1.28 | ||
| Q3 25 | $0.57 | $-1.81 | ||
| Q2 25 | $0.22 | $-1.17 | ||
| Q1 25 | $0.21 | $-1.57 | ||
| Q4 24 | $-0.03 | $-1.34 | ||
| Q3 24 | $1.99 | $-1.40 | ||
| Q2 24 | $0.30 | $-1.52 | ||
| Q1 24 | $0.51 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $421.0M |
| 总债务越低越好 | $18.9M | — |
| 股东权益账面价值 | $1.1B | $-80.0M |
| 总资产 | $1.3B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.02× | — |
8季度趋势，按日历期对齐
现金及短期投资INVXRARE
| Q4 25 | — | $421.0M | ||
| Q3 25 | — | $202.5M | ||
| Q2 25 | — | $176.3M | ||
| Q1 25 | — | $127.1M | ||
| Q4 24 | — | $174.0M | ||
| Q3 24 | — | $150.6M | ||
| Q2 24 | $185.6M | $480.7M | ||
| Q1 24 | $202.2M | $112.3M |
总债务INVXRARE
| Q4 25 | $18.9M | — | ||
| Q3 25 | $20.1M | — | ||
| Q2 25 | $34.8M | — | ||
| Q1 25 | $19.7M | — | ||
| Q4 24 | $24.9M | — | ||
| Q3 24 | $12.4M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益INVXRARE
| Q4 25 | $1.1B | $-80.0M | ||
| Q3 25 | $1.0B | $9.2M | ||
| Q2 25 | $995.6M | $151.3M | ||
| Q1 25 | $978.4M | $144.2M | ||
| Q4 24 | $958.2M | $255.0M | ||
| Q3 24 | $904.4M | $346.8M | ||
| Q2 24 | $352.5M | $432.4M | ||
| Q1 24 | $344.3M | $140.3M |
总资产INVXRARE
| Q4 25 | $1.3B | $1.5B | ||
| Q3 25 | $1.3B | $1.2B | ||
| Q2 25 | $1.2B | $1.3B | ||
| Q1 25 | $1.2B | $1.3B | ||
| Q4 24 | $1.2B | $1.5B | ||
| Q3 24 | $1.1B | $1.5B | ||
| Q2 24 | $1.0B | $1.6B | ||
| Q1 24 | $1.0B | $1.3B |
负债/权益比INVXRARE
| Q4 25 | 0.02× | — | ||
| Q3 25 | 0.02× | — | ||
| Q2 25 | 0.03× | — | ||
| Q1 25 | 0.02× | — | ||
| Q4 24 | 0.03× | — | ||
| Q3 24 | 0.01× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $52.2M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | — | $-100.8M |
| 自由现金流率自由现金流/营收 | — | -48.6% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | 3.74× | — |
| 过去12个月自由现金流最近4个季度 | — | $-472.0M |
8季度趋势，按日历期对齐
经营现金流INVXRARE
| Q4 25 | $52.2M | $-99.8M | ||
| Q3 25 | $48.4M | $-91.4M | ||
| Q2 25 | $59.2M | $-108.3M | ||
| Q1 25 | $31.1M | $-166.5M | ||
| Q4 24 | $36.3M | $-79.3M | ||
| Q3 24 | $21.7M | $-67.0M | ||
| Q2 24 | $22.8M | $-77.0M | ||
| Q1 24 | $12.6M | $-190.7M |
自由现金流INVXRARE
| Q4 25 | — | $-100.8M | ||
| Q3 25 | — | $-92.7M | ||
| Q2 25 | — | $-110.7M | ||
| Q1 25 | — | $-167.8M | ||
| Q4 24 | — | $-79.5M | ||
| Q3 24 | — | $-68.6M | ||
| Q2 24 | $16.6M | $-79.0M | ||
| Q1 24 | $7.8M | $-193.9M |
自由现金流率INVXRARE
| Q4 25 | — | -48.6% | ||
| Q3 25 | — | -58.0% | ||
| Q2 25 | — | -66.5% | ||
| Q1 25 | — | -120.5% | ||
| Q4 24 | — | -48.3% | ||
| Q3 24 | — | -49.2% | ||
| Q2 24 | 12.7% | -53.7% | ||
| Q1 24 | 6.1% | -178.2% |
资本支出强度INVXRARE
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 0.8% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 1.0% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 1.2% | ||
| Q2 24 | 4.7% | 1.4% | ||
| Q1 24 | 3.7% | 3.0% |
现金转化率INVXRARE
| Q4 25 | 3.74× | — | ||
| Q3 25 | 1.23× | — | ||
| Q2 25 | 3.86× | — | ||
| Q1 25 | 2.11× | — | ||
| Q4 24 | 1.14× | — | ||
| Q3 24 | 0.26× | — | ||
| Q2 24 | 2.39× | — | ||
| Q1 24 | 0.77× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
INVX
| Products | $202.7M | 74% |
| Leasing | $42.3M | 15% |
| Services | $28.6M | 10% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
